CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells

By Jian Wang, P. Sakariassen, O. Tsinkalovsky, H. Immervoll, S. Bøe, A. Svendsen, L. Prestegarden, G. Røsland, F. Thorsen, L. Stuhr and 3 more. International Journal of Cancer, 2008

601 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/5a76bc45541171d07e5f1043229c51bd27d5c2c6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Oncology

Citations in the corpus

Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma (2010, background): “Although more recent investigations have called into question the unique tumour-initiating properties of the CD133 + subpopulatio”
Cancer stem cells: impact, heterogeneity, and uncertainty. (2012, background): “Yet subsequent studies found tumorigenic activity among both CD133+ and CD133 brain tumor cells (Beier et al., 2007; Chen et al., 2010; Joo et al., 2008; Wang et al., 2008).”
The therapeutic promise of the cancer stem cell concept. (2010, background): “In addition, a separate study indicated the possibility of interconversion of CD133– and CD133+ glioma cell phenotypes (45), but it did not demonstrate that CD133– glioma cells represent CSCs according to the consensus definition (12).”
Heterogeneity in cancer: cancer stem cells versus clonal evolution. (2009, background): “…a robust marker of brain tumor stem cells in initial studies (Singh et al., 2004; Bao et al., 2006), but more recent studies have found that this marker does not distinguish tumorigenic from nontumorigenic cells in many other brain tumors (Joo et al., 2008; Ogden et al., 2008; Wang et al., 2008).”
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized (2010, background): “Nonetheless, the robustness of some cancer stem cell markers has been questioned (Joo et al., 2008; Ogden et al., 2008; Wang et al., 2008) and it remains to be determined how generalizable the model is.”
SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma (2009, background): “These data, which are consistent with those of others (Beier et al., 2007; Joo et al., 2008; Ogden et al., 2008; Wang et al., 2008), suggest that CD133 may not be a universal enrichment marker for TSC/TIC in GBMs.”
Multicellular tumor spheroids: an underestimated tool is catching up again. (2010, methodology): “…assays both when using the entire cellular material from tumor biopsies or some tumor cell subpopulations defined and enriched according to their surface expression pattern (Bao et al., 2006a,b; Galli et al., 2004; Lu et al., 2009; Singh et al., 2003, 2004; Wang et al., 2008; Zhang et al., 2006).”
Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells (2009, unknown): “The role of HIF2a in tumors that are not driven by CD133 expression (Beier et al., 2007; Zheng et al., 2007; Wang et al., 2008) is still unresolved, but we did not observe HIF2a expression in a rat glioma cell line in which CD133-negative cells were reported to be tumorigenic (Zheng et al., 2007).”
Integrin alpha 6 regulates glioblastoma stem cells (2010, methodology): “Prior to coverslip application, nuclei were counterstained with Hoechst and imaging done with a Leica SP-5 confocal microscope as described previously (Wang et al., 2008b).”